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Irritable  bowel  syndrome  (IBS)  is a common  chronic  disorder.  IBS  diagnosis  is  a  diagnosis  of  exclusion
since  there  are no  blood  tests,  radiological  or endoscopic  examinations  for this  disorder.  Although  several
attempts  have  been  made  to develop  a  symptoms-based  diagnosis,  such  systems  are not  widely  used  in
clinics. Several  tests  and  examinations  measuring  pathological  ﬁndings  in  IBS  have  been  considered
for  the  diagnosis  of  IBS, but none  of them  has  proved  useful  as  a biomarker.  Abnormalities  in the cell
densities  of  rectal  peptide  YY (PYY)  and  somatostatin  cells  have  been  reported  in IBS patients.  The  aim
of the present  study  was  to determine  the  utility  of these  abnormalities  as  biomarkers  for the  diagnosis
of IBS.  Patients  with  IBS  established  according  to  Rome  III  criteria  (n = 101)  were  included  in this  study
(71  females  and  30  males  with  a mean  age  of 35 years;  range  18–61  years),  and  62 healthy  subjects
(38 females  and 24 males  with  a mean  age  of 41 years;  range  18–65  years)  were  recruited  as controls.
Both the  patients  and  controls  underwent  colonoscopy  during  which  rectal  biopsy  samples  were  taken.
The  tissue  samples  were  immunostained  for PYY  and  somatostatin,  and  the  number  of stained  cells
was  quantiﬁed  relative  to both  the  area  of  epithelial  cells  and  per  microscopic  ﬁeld.  The  density  of PYY
cells  was  signiﬁcantly  lower  in IBS  patients  than  in  the  healthy  controls  (P < 0.0001);  receiver  operator
characteristic  (ROC)  analysis  revealed  an  area  under  the  ROC  curve  (AUC)  of  0.99. The  somatostatin  cell
density in IBS  patients  was  higher  than  in  the  controls  (P <  0.0001);  ROC  analysis  revealed  an  AUC  of  0.86.
The  densities  of  the  rectal  PYY  and  somatostatin  cells  appear  to  be clinically  effective  biomarkers  for  IBS.
Furthermore,  measurement  of these  parameters  is inexpensive,  rapid and  does  not  require  considerable
experience  or sophisticated  equipment.
© 2015  The  Authors.  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the  CC  BY-NC-NDntroduction
Irritable bowel syndrome (IBS) is a common chronic disorder
hat affects between 5% and 20% of the population of the Western
orld [1,2], and yet there are currently no blood tests, radiological
r endoscopic examinations for diagnosing the disorder. Although
everal attempts have been made to obtain a diagnosis based on
ymptom assessments similar to those used in psychiatry and
heumatology [3–9], IBS diagnosis in clinical practice remains a
rocess of exclusion [1,10–12]. Thus, a diagnosis of IBS can only
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be reached by conducting extensive expensive examinations and
tests to exclude organic causes for the patient’s symptoms.
Several abnormalities in the gastrointestinal endocrine cells
have been described in IBS patients [13–27]. These abnormali-
ties are believed to play an important role in the pathophysiology
of IBS and represent a potential tool for the treatment of this
disorder [28,29]. A previous study [30] found the cell density of
rectal peptide YY (PYY) cells to be decreased, and that of somato-
statin to be increased relative to healthy subjects. It has been
suggested that these abnormalities can be used in the diagnosis
of IBS [30]. However, that study included 50 patients and 27 con-
trols, and the subtypes of IBS of the included patients were only
those with diarrhea or constipation as the predominant symp-
tom. The present study was undertaken to investigate the efﬁcacy
of the densities of rectal PYY and somatostatin cells as biomark-
ers for the diagnosis of IBS in a larger cohort of IBS patients and
with a larger group of healthy controls for comparison than was
used in the previous study. Furthermore, IBS patients with any
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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f the IBS subtypes—constipation-predominant (IBS-C), diarrhea-
redominant (IBS-D) or mixed (IBS-M)—were included.
aterial and methods
atients and controls
One hundred and one patients suffering from IBS according to
ome III criteria [9] were included in this study. Pregnant or lactat-
ng women, patients with clinically signiﬁcant systemic diseases,
rug abuse, serious psychiatric diseases, and abdominal surgery,
ith the exception of appendectomy, cesarean section and hys-
erectomy were excluded. The cohort comprised 71 females and 30
ales with a mean age of 35 years (range 18–61 years); 45 patients
ad IBS-D, 14 had IBS-M and 42 had IBS-C. All of the patients had a
ong duration of IBS symptoms i.e. greater than 10 years, and their
nset of IBS symptoms was not associated with a bout of gastroen-
eritis. The patients submitted to a physical examination and blood
ests to exclude inﬂammation, liver and pancreas diseases, and
hyroid dysfunction. Celiac disease was excluded by histopatho-
ogical examination of duodenal biopsy samples. Forty-ﬁve of these
atients used proton-pump inhibitors on demand, 18 were med-
cated with angiotensin II-receptor antagonist against hypertonia,
5 with statins against high blood cholesterol levels, and 2 with
evothyroxine against hypothyroidosis.
The controls comprised 62 subjects (38 females and 24
ales; mean age 41 years, range 18–65 years) who under-
ent colonoscopy with rectal biopsy sampling. The reasons for
olonoscopy in these subjects were gastrointestinal bleeding,
here the bleeding source was identiﬁed as hemorrhoids (n = 36),
r angiodysplasia (n = 4), and otherwise healthy subjects with
ealth worries caused by a relative(s) being diagnosed with colon
arcinoma (n = 22). Five of these subjects were treated for hyper-
onia with angiotensin II-receptor antagonist, 4 with statins and 2
ith levothyroxine.
The study was performed in accordance with the Declaration of
elsinki and was approved by the Regional Committee for Medi-
al and Health Research Ethics West, Bergen, Norway. All subjects
rovided verbal and written consent to participate.
olonoscopy, histopathology and immunohistochemistry
A standard colonoscopy procedure was performed on all of
he patients and controls, and four biopsy samples were taken
rom the dorsal wall of the rectum about 15 cm from the anus
n each patient. The biopsy samples were ﬁxed overnight in 4%
uffered paraformaldehyde, embedded in parafﬁn and then sec-
ioned at 5 m.  The sections were stained with hematoxylin–eosin
nd immunostained with ultraView universal DAB detection kit
v1.02.0018, Venata Medical Systems, Basel, Switzerland) using
he BenchMark Ultra IHC/ISH staining module (Venata Medical
ystems). The sections were incubated with the primary antibod-
es for 32 min  at 37 ◦C. The primary antibodies were polyclonal
nti-porcine peptide YY (PYY; code no. PYY11A, Alpha Diagnostic,
an Antonio, TX, USA) and polyclonal rabbit anti-synthetic human
omatostatin (code no. A566, Dako, Glostrup, Denmark). Nega-
ive and positive controls were performed as described elsewhere
31,32].
uantiﬁcation of immunoreactive cell densities
The densities of rectal PYY and somatostatin cells were quan-
iﬁed by computerized image analysis and counting the number
f positive cells in a microscopic ﬁeld. Measurements using com-
uterized image analysis were performed on a computer linked
o a microscope (BX 43, Olympus, Tokyo, Japan) equipped with as 67 (2015) 12–19 13
digital camera (DP 26, Olympus), using Olympus cellSens imaging
(version 1.7) software. The numbers of PYY- and somatostatin-
immunoreactive cells were counted in ten randomly chosen
microscopic ﬁelds, and the area of epithelial cells was  measured.
The number of endocrine cells in each ﬁeld was counted manu-
ally by pointing and clicking the computer mouse, and the area of
the epithelium containing these cells was drawn manually using
the computer mouse. A ×40 objective was  used, for which each
frame (ﬁeld) on the monitor represented a tissue area of 0.035 mm2.
Immunostained sections from the patients and controls were coded
and mixed, and measurements were made by the same person
(M.E.) who was blind to the identity of the sections (i.e., IBS or
control).
Statistical analysis
Differences in gender between patients and controls were
tested using Fisher’s exact test. Differences in the age proﬁle were
tested using the Mann–Whitney non-parametric test. Differences
between controls and all IBS patients (IBS-total), and between IBS-
D, IBS-M and IBS-C patients were tested using the Kruskal–Wallis
non-parametric test with Dunn’s post-test. The data are presented
as mean ± SEM values, and differences with P < 0.05 were consid-
ered to be statistically signiﬁcant.
Results
Patients and controls
The gender and age distributions did not differ signiﬁcantly
between the patients and the controls (P = 0.2 and 0.7, respectively).
Colonoscopy, histopathology and immunohistochemistry
The endoscopic and histopathological appearance of the colon
and rectum was normal in both the patients and controls. PYY-
and somatostatin-immunoreactive cells were found mostly in the
crypts of Lieberkühn in both the patients and the controls, and were
basket- or ﬂask-shaped, sometimes with a long basal cytoplasmic
process.
Quantiﬁcation of immunoreactive cell density
PYY cell density
The densities of PYY cells as determined by computerized image
analysis and as counted per microscopic ﬁeld are summarized
in Tables 1 and 2 and depicted graphically in Figs. 1 and 2. The
Kruskal–Wallis test revealed signiﬁcant differences between the
IBS patients and the controls (P < 0.0001). Dunn’s post-test revealed
that PYY cell density was  lower in IBS-total and all three of the IBS
subgroups relative to the controls (P < 0.0001 for all). The results
of receiver operator characteristic (ROC) analysis with the area
under the ROC curve (AUC), 95% conﬁdence intervals (95% CIs)
and P values for PYY cell density are shown in Figs. 3 and 4. The
sensitivity and speciﬁcity for cut-off values of <188 cells/mm2 and
<6 cells/microscopic ﬁeld for a diagnosis of IBS are given in Table 3.
Somatostatin cell density
The somatostatin cell density was  signiﬁcantly higher in IBS
patients than in the controls (Tables 1 and 2; Figs. 5 and 6;
Kruskal–Wallis test, P < 0.0001). Dunn’s post-test revealed that the
increased somatostatin cell density was statistically signiﬁcant
in IBS-total and all of the IBS-subgroups relative to the controls
(P < 0.0001 for all). ROC curves (Figs. 7 and 8) for somatostatin
cell density, and the sensitivity and speciﬁcity for cut-off values
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Table 1
Densities of PYY and somatostatin cells in controls and patients (measured by computerized image analysis), expressed as the number of cells relative to the area of epithelial
cells.  Data are mean ± SEM values.
Endocrine cell type Controls IBS-total IBS-D IBS-M IBS-C
Cells/mm2 Cells/mm2 Cells/mm2 Cells/mm2 Cells/mm2
PYY 430 ± 9 144 ± 4*** 145 ± 6*** 128 ± 6*** 148 ± 5***
Somatostatin 156 ± 7 251 ± 8*** 265 ± 2 *** 257 ± 1*** 234 ± 7***
*** P < 0.0001 vs. controls.
Table 2
Densities of PYY and somatostatin cells in controls and IBS patients expressed as the number of cells per microscopic ﬁeld. Data are mean ± SEM value.
Endocrine cell type Controls IBS-total IBS-D IBS-M IBS-C
Cells/ﬁeld Cells/ﬁeld Cells/ﬁeld Cells/ﬁeld Cells/ﬁeld
PYY 8.4 ± 0.3 4.5 ± 0.1*** 4.6 ± 0.2*** 4.5 ± 0.3*** 4.6 ± 0.2***
Somatostatin 5.0 ± 0.2 9.8 ± 0.8*** 8.9 ± 0.2*** 8.3 ± 0.3*** 8.4 ± 0.2***
*** P < 0.0001 vs. controls.
Fig. 1. Rectal PYY-immunoreactive cells in (A) a control subject and (B) a patient with IBS.
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Fig. 2. Density of PYY cells expressed relative to the area of epithelial cells (A) and as the number of cells per microscopic ﬁeld (B) in 10 randomly chosen ﬁelds in tissue
samples  taken from the controls and IBS-total, IBS-D, IBS-M, and IBS-C patients. ***P < 0.0001 vs. control group.
Table 3
Sensitivity and speciﬁcity of the PYY cell density as a biomarker for IBS at cut-off values of <188 cells/mm2 epithelium and <6 cells/microscopic ﬁeld.
IBS-total IBS-D IBS-M IBS-C
Cells/mm2 Cells/ﬁeld Cells/mm2 Cells/ﬁeld Cells/mm2 Cells/ﬁeld Cells/mm2 Cells/ﬁeld
Sensitivity (%) 89 90 87 87 100 100 88 88
Speciﬁcity (%) 87 95 87 89 87 89 87 89
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Fig. 3. Results of ROC analysis for PYY cell density as measured relative to the area of epithelial cells in (A) IBS-total (AUC = 0.95, 95% CI = 0.92–0.98, P < 0.0001), (B) IBS-D
(AUC  = 0.94, 95% CI = 0.90–0.98, P < 0.0001), (C) IBS-M (AUC = 0.99, 95% CI = 0.97–1.00, P < 0.0001) and (D) IBS-C (AUC = 0.95, 95% CI = 0.91–0.98, P < 0.0001). AUC = 1 represents
a  perfect test, and AUC = 0.5 represents a non-discriminating test.
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Fig. 4. Results of ROC analysis for PYY cell density measured in 10 randomly chosen microscopic ﬁelds in (A) IBS-total (AUC = 0.99, 95% CI = 0.98–1.00, P < 0.0001), (B) IBS-D
(AUC  = 0.99, 95% CI = 0.97–1.00, P < 0.0001), (C) IBS–M (AUC = 1.0, 95% CI = 1.00–1.00, P < 0.0001) and (D) IBS-C (AUC = 0.99, 95% CI = 0.98–1.00, P < 0.0001).
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Fig. 5. Somatostatin-immunoreactive cells in rectal tissue from a control subject (A) and a patient with IBS (B).
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Fig. 6. Somatostatin cell density expressed relative to the area of epithelial cells (A) and (B) as the number of cells per microscopic ﬁeld in IBS-total, IBS-D, IBS-M and IBS-C
patients. ***P < 0.0001 vs. control group.
Table 4
Sensitivity and speciﬁcity of the somatostatin cell density as a biomarker for IBS at cut-off values of >182 cells/mm2 epithelium and >6 cells/microscopic ﬁeld.
IBS-total IBS-D IBS-M IBS-C
Cells/mm2 Cells/ﬁeld Cells/mm2 Cells/ﬁeld Cells/mm2 Cells/ﬁeld Cells/mm2 Cells/ﬁeld
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Speciﬁcity (%) 81 90 81 
f >182 cells/mm2 and >6 cells/microscopic ﬁeld for a diagnosis of
BS are given in Table 4.
iscussion
The diagnosis of IBS is performed via a process of exclusion,
hereby extensive examinations and tests are conducted to
xclude other organic diseases [1,10–12]. Attempts have been
ade to achieve a positive symptom-based diagnosis similar to
hose used in psychiatry [3–9,33], which culminated in the estab-
ishment of the symptoms-based Rome I diagnostic criteria for IBS
n 1988 by an international group of gastroenterologists. These cri-
eria were succeeded by reﬁnements in 1999 (Rome II criteria) and
006 (Rome III criteria). The Rome criteria are not widely used in
urrent clinical practice [9,11,34] because of the potential to miss
rganic diseases that mimic  IBS symptoms but have a different
athophysiology and treatments [10,11,34,35]. Several tests and
xaminations measuring gut motility, visceral hypersensitivity,100 93 93 92
81 90 81 90
autonomic reactivity, mucosal inﬂammation, fecal proteases, gut
ﬂora, serum antibodies, gene expression and food allergies have
been considered for the diagnosis of IBS, but none has proven
useful as a biomarker for IBS diagnosis [10–13,36,37].
A panel of ten serological biomarkers that are commonly con-
sidered in the differential diagnosis for IBS patients, such as those
for inﬂammatory bowel disease and coeliac disease, were exam-
ined by Lembo et al. as biomarkers for the diagnosis of IBS [38].
These authors used the smart Diagnostic Algorithm and found an
AUC of 0.763 for this panel. Jones et al. added a further 24 sero-
logical biomarkers to that panel (thus totalling 34), and examined
them together with 4 psychological markers [39]. The combination
of these 34 markers has been reported to be good for differenti-
ating IBS from health (AUC = 0.81), and was improved by adding
the four psychological markers (AUC = 0.92) [39]. However, the use
of serological biomarkers common to other gastrointestinal dis-
eases cannot be considered as an IBS-speciﬁc biomarker; rather, it
is yet another method of exclusion diagnosis. Furthermore, com-
bining these serological markers with psychological markers, with
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Fig. 7. ROC curves for somatostatin cell density expressed relative to the area of epithelial cells in (A) IBS-total (AUC = 0.86, 95% CI = 0.79–0.92, P < 0.0001), (B) IBS-D (AUC = 0.83,
95%  CI = 0.73–0.93, P < 0.0001), (C) IBS-M (AUC = 0.90, 95% CI = 0.83–0.97, P < 0.0001) and (D) IBS-C (AUC = 0.86, 95% CI = 0.78–0.94, P < 0.0001).
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Fig. 8. ROC analysis for somatostatin cell density expressed as the number of cells per microscopic ﬁeld in (A) IBS-total (AUC = 0.93, 95% CI = 0.89–0.98, P < 0.0001), (B) IBS-D
(AUC  = 0.92, 95% CI = 0.86–0.98, P < 0.0001), (C) IBS-M (AUC = 0.94, 95% CI = 0.90–0.98, P < 0.0001) and (D) IBS-C (AUC = 0.93, 95% CI = 0.88–0.98, P < 0.0001).
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[
immunoreactivity intensity in the ileum of patients with irritable bowel dis-
ease. Mol  Med  Rep 2013;9:180–4.8 M. El-Salhy et al. / P
he hypothesis that anxiety and depression are more likely to result
rom the symptoms of the disorder [40], is not logical. Ultimately,
his approach is complicated, time consuming, expensive and dif-
cult to apply in everyday clinical practice.
Several abnormalities in the gastrointestinal endocrine cells,
ncluding in the stomach and the small and large intestines, have
een reported in IBS patients [1,29,41], and these abnormalities
ppear to play an important role in the pathophysiology of the
isease [28,29]. The density of duodenal chromogranin A cells has
een proposed as a biomarker for the diagnosis of IBS [42], and is
eportedly effective at differentiating IBS from the healthy condi-
ion (AUC = 97). The ﬁndings of the present study suggest two new
iomarkers for the diagnosis of IBS: the cell densities of rectal PYY
nd somatostatin cells.
PYY cell density is a good biomarker for differentiating IBS from
he healthy condition, with AUCs of 0.95 and 0.99 when expressed
elative to the area of epithelial cells and per microscopic ﬁeld,
espectively. When analyzed according to the various IBS subtypes,
he AUCs were 0.94, 0.99 and 0.95 for the density of PYY cells
xpressed relative to the areas of epithelial cells in IBS-D, IBS-M
nd IBS-C, respectively, and 0.99, 1.0 and 0.99, respectively, when
xpressed per microscopic ﬁeld. Thus, the density of rectal PYY
ells appears to be a good biomarker for all IBS subtypes. Can a
lood-based biomarker assay for circulating PYY and somatostatin
e used? PYY cells occur in the ileum, colon and rectum [30,43,44].
imilarly Somatostatin cells are localized in the stomach, small- and
arge intestine [15,30,43–46]. Hence circulating somatostatin and
YY would reﬂect the release of these hormones from the cells in
ll these segments. There was no difference between IBS patients
nd controls regarding fasting and postprandial PYY plasma lev-
ls [47]. Similarly, there was no signiﬁcant difference in fasting
omatostatin plasma level between IBS patients and controls [48].
hus, measuring the circulating PYY and somatostatin is of no use
s a marker for the diagnosis of IBS.
Similarly, the density of rectal somatostatin cells appears to be
 good biomarker for differentiating between IBS and the healthy
ondition, with AUCs of 0.86 and 0.93 when expressed relative to
he area of epithelial cells and per microscopic ﬁeld, respectively.
his parameter is equally good as a biomarker for all of the IBS
ubtypes, with AUCs of 0.83, 0.90 and 0.86 for IBS-D, IBS-M and IBS-
, respectively, expressed relative to the area of epithelial cells, and
.93, 0.92 and 0.93, respectively, when expressed per microscopic
eld.
These ﬁndings establish that PYY and somatostatin cell densi-
ies can be used as biomarkers for IBS, clearly differentiating disease
rom the healthy condition, but the question as to whether they dif-
erentiate IBS from other gastrointestinal diseases that mimic  IBS
ymptoms has yet to be answered deﬁnitively. The most commonly
issed gastrointestinal diseases during symptom-based diagnosis
re celiac disease, inﬂammatory bowel diseases including micro-
copic colitis and colorectal cancer [49,50]. It has been reported
hat plasma levels of PYY are increased in celiac disease [51], and
he density of large-intestinal PYY cells is increased in lymphocytic
olitis, unchanged in ulcerative colitis and in colon and rectal can-
ers, and decreased in Crohn’s disease [32,44,52,53]. It therefore
ppears that with the exception of Crohn’s disease, the density of
ectal PYY cells can potentially be used to differentiate IBS from
hese gastrointestinal diseases. Large-intestinal somatostatin cell
ensity is not changed in lymphocytic colitis or ulcerative colitis,
nd is decreased in colon and rectal cancers [32,44,52,53]. There-
ore, as with PYY cell density, the density of rectal somatostatin
ells seems likely to be able to differentiate IBS from some other
astrointestinal diseases.
The rectum is easily accessible for biopsy sampling and is
enerally well tolerated by patients, and immunohistochemistry
s inexpensive and used routinely in all pathology laboratories.
[
[s 67 (2015) 12–19
Furthermore, manually counting the PYY and somatostatin cells in
ten microscopic ﬁelds is rapid and does not require sophisticated
equipment or considerable experience.
Conclusion
This study has revealed two new biomarkers for the diagnosis of
IBS, namely the densities of the rectal PYY and somatostatin cells.
These two biomarkers fulﬁll the requirements for clinically use-
ful biomarkers in that they have been shown to possess a good
ability to differentiate IBS from the healthy condition, may be
able to differentiate IBS from other gastrointestinal diseases that
mimic  IBS symptoms, and are inexpensive, simple, easy to per-
form and do not require considerable experience or sophisticated
equipment.
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